366 related articles for article (PubMed ID: 16510541)
1. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
[TBL] [Abstract][Full Text] [Related]
2. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in rodents and primates.
Atack JR; Wafford KA; Tye SJ; Cook SM; Sohal B; Pike A; Sur C; Melillo D; Bristow L; Bromidge F; Ragan I; Kerby J; Street L; Carling R; Castro JL; Whiting P; Dawson GR; McKernan RM
J Pharmacol Exp Ther; 2006 Jan; 316(1):410-22. PubMed ID: 16183706
[TBL] [Abstract][Full Text] [Related]
3. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women.
Chandrasekaran A; McKeand WE; Sullivan P; DeMaio W; Stoltz R; Scatina J
Drug Metab Dispos; 2009 Jun; 37(6):1219-25. PubMed ID: 19273530
[TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
Prakash C; Cui D; Baxter JG; Bright GM; Miceli J; Wilner K
Drug Metab Dispos; 1998 May; 26(5):448-56. PubMed ID: 9571226
[TBL] [Abstract][Full Text] [Related]
5. Absorption, metabolism, and excretion of [14C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects.
Ohmori S; Miura M; Toriumi C; Satoh Y; Ooie T
Drug Metab Dispos; 2007 Sep; 35(9):1624-33. PubMed ID: 17567733
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
7. Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023.
Atack JR
Adv Pharmacol; 2009; 57():137-85. PubMed ID: 20230761
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.
de Haas SL; de Visser SJ; van der Post JP; de Smet M; Schoemaker RC; Rijnbeek B; Cohen AF; Vega JM; Agrawal NG; Goel TV; Simpson RC; Pearson LK; Li S; Hesney M; Murphy MG; van Gerven JM
J Psychopharmacol; 2007 Jun; 21(4):374-83. PubMed ID: 17092968
[TBL] [Abstract][Full Text] [Related]
11. Disposition and metabolism of radiolabeled casopitant in humans.
Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
[TBL] [Abstract][Full Text] [Related]
12. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans.
Mannens GS; Hendrickx J; Janssen CG; Chien S; Van Hoof B; Verhaeghe T; Kao M; Kelley MF; Goris I; Bockx M; Verreet B; Bialer M; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):554-65. PubMed ID: 16936066
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
14. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
15. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
16. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
18. Absorption, metabolism, and excretion of [(14)C]MK-0524, a prostaglandin D(2) receptor antagonist, in humans.
Karanam B; Madeira M; Bradley S; Wenning L; Desai R; Soli E; Schenk D; Jones A; Dean B; Doss G; Garrett G; Crumley T; Nirula A; Lai E
Drug Metab Dispos; 2007 Jul; 35(7):1196-202. PubMed ID: 17431030
[TBL] [Abstract][Full Text] [Related]
19. Disposition and biotransformation of the antiretroviral drug nevirapine in humans.
Riska P; Lamson M; MacGregor T; Sabo J; Hattox S; Pav J; Keirns J
Drug Metab Dispos; 1999 Aug; 27(8):895-901. PubMed ID: 10421616
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
